BioCryst Pharmaceuticals, Inc.
BCRX
$7.40
$0.182.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 60.77% | 47.61% | 39.88% | 7.81% | 8.33% |
| Total Depreciation and Amortization | 5.06% | 5.24% | 11.11% | 18.24% | 27.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.73% | -33.70% | -31.58% | 7.77% | 13.37% |
| Change in Net Operating Assets | -169.38% | 7.08% | -1.45% | 1.45% | 45.03% |
| Cash from Operations | 45.32% | 49.37% | 31.60% | 22.99% | 41.22% |
| Capital Expenditure | 48.15% | 53.13% | -45.41% | -102.99% | -60.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 141.53% | 130.95% | 119.53% | 103.38% | -1.93% |
| Cash from Investing | 140.00% | 124.50% | 117.69% | 102.22% | -2.54% |
| Total Debt Issued | -- | -100.00% | -100.00% | 310.55% | 310.55% |
| Total Debt Repaid | 99.29% | 98.95% | 99.19% | -- | -- |
| Issuance of Common Stock | -53.25% | -66.79% | -75.01% | -58.21% | -41.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 78.21% | 79.56% | 79.39% | -- | -- |
| Cash from Financing | -117.73% | -112.33% | -104.32% | -69.26% | -63.10% |
| Foreign Exchange rate Adjustments | -358.56% | 420.47% | 404.17% | -72.56% | -36.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.84% | 44.26% | 46.46% | 70.91% | 3.82% |